Lpath Inc fka LPTN

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

stockmasterflash Free

11/30/16 7:03 PM

Post #712

Pancoast

Just got hired by a BK11 pennystock scam

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126899752

Scott R. Pancoast Joins the Imaging3 Team

Imaging3, Inc. (OTCQB:IGNG) announced today that it has entered into a consulting agreement with Scott R. Pancoast, whereby Mr. Pancoast will serve as special advisor to the company's executive team and its board of directors. Once the company has secured directors and officers insurance, Mr. Pancoast will be named executive chairman of the board, where he will also have an executive role; at that time, Dane Medley, currently chief executive officer and president, will relinquish his CEO role and remain president.

Scott Pancoast most recently served as chief executive officer and board member of Lpath, Inc., a biotech start-up, where he built a world-class team of executives that: took Lpath public and later uplisted it to Nasdaq; forged partnerships with Pfizer, Biogen Idec, Merck-Serono, and the Department of Defense; and raised over $150 million through private and public offerings, government grants, and collaborations. Prior to that, Mr. Pancoast served as executive vice president of Western States Investment Group, a privately owned venture-investment firm, whose holdings included the start-up that introduced the "ear thermometer" [sold to Wyeth/Pfizer]; an RFID start-up that had a leading position in the electronic vehicle-identification market [sold to a JP Morgan fund]; and a medical-device start-up that designed diagnostic and therapeutic devices for gastro-esophageal reflux disease [sold to Medtronic]. In his career, Mr. Pancoast has served on the board of directors of over 15 entities, including three public companies, and been CEO or interim CEO for seven entities. He is a graduate of the University of Virginia, summa cum laude, and the Harvard Business School, with honors.

Dane Medley stated, "We are extremely gratified to have someone with Scott's background and pedigree join the Imaging3 team. Scott shares our vision of Imaging3 bringing a disruptive technology to the radiology marketplace and consequently achieving sizable market share, while at the same time improving the quality of healthcare, especially for children."

Added Scott Pancoast, "I was presented with many opportunities over the last couple of years, but it was the promise of Imaging3 that brought me out of retirement. After conducting extensive due diligence, I am convinced of the upside potential of Imaging3's technology, and I look forward to working with Dane as we build out the management team and position the company for success."

KantKill

10/18/16 4:16 PM

Post #709

I have no malicious intent whatsoever, I am not sure even whats happening.

KantKill

10/11/16 7:29 PM

Post #707

Re: #706: @KantKill - The S4 is bad news for LPTN shareholders ---

Things may not be all bad, some of us just felt like it was kind of the Apollo show w/ LPTN makng guest appearances --- I guess when LPTN only makes up 4%.1 or 4.2% (dpenending on cash vs debt at completion) it makes sense --

Sold near 4, but lookin for possible re-entry...

Someone please post with some good news, half my reason for stating as such is to have someone swoop in to save the day with a better understanding of the situation as I've only gone skin deep.

KantKill

10/11/16 6:30 PM

Post #706

The S4 is bad news for LPTN shareholders ---

This is a joke, its as if its written solely to Apollo... Please correct me if, and where I am wrong...

A reverse split? 80 cent share price ? (separate points)

To the Stockholders of Lpath, Inc. and Apollo Endosurgery, Inc.:

Lpath, Inc. ("Lpath") and Apollo Endosurgery, Inc. ("Apollo") have entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") pursuant to which a wholly-owned subsidiary of Lpath will merge with and into Apollo, with Apollo surviving as a wholly-owned subsidiary of Lpath (the "merger"). Apollo and Lpath believe that the merger will result in a medical device company focused on the development and global distribution of less invasive products used in the treatment of obesity and other gastrointestinal disorders.

Immediately prior to the effective time of the merger, each share of Apollo preferred stock will be converted into shares of Apollo common stock at a ratio determined in accordance with the Apollo certificate of incorporation then in effect. At the effective time of the merger, each share of Apollo common stock will be converted into the right to receive an estimated 0.314 shares of Lpath common stock (the "exchange ratio"), subject to adjustment to account for the effect of a reverse stock split of Lpath common stock, at a ratio of one new share for every five and one half shares outstanding (1:5.5), to be implemented prior to the consummation of the merger as discussed in this proxy statement/prospectus/information statement. The estimated exchange ratio calculation contained herein is based upon Lpath's capitalization immediately prior to the date of this proxy statement/prospectus/information statement, and will be adjusted to account for the issuance of any additional shares of Lpath common stock prior to the consummation of the merger. Lpath will assume outstanding and unexercised warrants to purchase Apollo capital stock and options to purchase Apollo common stock, and they will be converted into warrants and options, as applicable, to purchase Lpath common stock. Lpath stockholders will continue to own and hold their existing shares of Lpath common stock. Immediately following the consummation of the merger, Apollo stockholders, warrantholders and optionholders will own approximately 95.8% of the fully-diluted common stock of Lpath, with Lpath stockholders, optionholders and warrantholders, whose shares of Lpath stock will remain outstanding after the merger, holding approximately 4.2% of the fully-diluted common stock of Lpath, subject to a reduction of 0.1% in the aggregate to Lpath stockholders, optionholders and warrantholders if Lpath's debt at the closing exceeds its net cash at the closing.

Shares of Lpath common stock are currently listed on The NASDAQ Capital Market under the symbol "LPTN." Prior to consummation of the merger, Lpath intends to file an initial listing application with The NASDAQ Global Market pursuant to NASDAQ "reverse merger" rules. After completion of the merger, Lpath will be renamed "Apollo Endosurgery, Inc." and expects to trade on The NASDAQ Global Market under the symbol "APEN." On , 2016, the last trading day before the date of this proxy statement/prospectus/information statement, the closing sale price of Lpath common stock was $ per share.

Lpath is holding a special meeting of stockholders in order to obtain the stockholder approvals necessary to complete the merger and related matters. At the Lpath special meeting, which will be held at a.m., Pacific Time, on , 2016 at , unless postponed or adjourned to a later date, Lpath will ask its stockholders to, among other things, adopt the Merger Agreement thereby approving the merger and the issuance of Lpath common stock, approve amendments to the Lpath amended and restated certificate of incorporation effecting a reverse stock split of Lpath common stock, at a ratio of one new share for every five and one half shares outstanding, which is referred to as the 1:5.5 reverse stock split, and an amendment to the amended and restated certificate of incorporation changing the Lpath corporate name to "Apollo Endosurgery, Inc.", and approve, on a non-binding advisory vote basis, compensation that will or may become payable by Lpath to its named

stocktrademan Free

09/30/16 4:33 PM

Post #705

fast and steady profit scan LPTN bullish 3.2801

normal chart

log chart

ClearlyStocks Free

09/08/16 4:07 PM

Post #704

LPTN $247 merger agreement with Apollo Endo

stocktrademan Free

09/05/16 4:22 PM

Post #703

LPTN bullish 2.35

stochastic5,3,3 oversold crossup scan

Shaka_Zulu Free

08/22/16 4:16 PM

Post #702

Target 5.88

BillBadaass Free

08/22/16 1:12 PM

Post #701

Re: #700: @Stockexpertpro - LPTN placed on Reg Sho list over 3

Intersting

Stockexpertpro Free

08/22/16 9:22 AM

Post #700

LPTN placed on Reg Sho list over 3 Million shares now sold short vs Tiny 1.9 Million share float

ClayTrader Free

08/19/16 4:53 PM

Post #699

* * $LPTN Video Chart 08-19-16 * *

Link to Video - click here to watch the technical chart video

Love4Money Free

08/19/16 12:17 PM

Post #698

Picked some up at 3.18.

ClearlyStocks Free

08/19/16 12:07 PM

Post #697

Craziness continues

Shaka_Zulu Free

08/17/16 12:33 PM

Post #696

Popping

Betchips

08/17/16 10:37 AM

Post #695

Re: #693: @Value_Investor - LOL, LPTN is up 0.01 today! The BV

Did you pick up shares today?

Betchips

08/17/16 12:34 AM

Post #694

Re: #693: @Value_Investor - LOL, LPTN is up 0.01 today! The BV

LPTN looking for strategic merger or buyout currently, book value significantly higher, could see a runner like STEM today on this low floater!

Value_Investor Free

08/05/16 4:16 PM

Post #693

Re: #673: @zino - Float 2.O3 million !!!!!

LOL, LPTN is up 0.01 today! The BV is $3.71 v.s. trading at $2.05!

Value_Investor Free

08/04/16 10:22 AM

Post #692

Re: #668: @zino - bought in this morning...glta

LPTN just hit $2.65! How could it crash to $1.81 in the next day? 100% strong manipulations by those very sick MMs and greedy shorters!

Value_Investor Free

08/03/16 2:47 PM

Post #691

Re: #678: @tob999 - Crazy low $5.1M market cap!! Insane!

LPTN just hit $2.17! $2.65 should be tested again very soon...

Value_Investor Free

08/03/16 11:58 AM

Post #690

Re: #677: @Shaka_Zulu - A close above 2.20 will be nice. Bullish

LOL, I even doubt if LPTN ever hit $2.65 just a week ago! There is a ridiculous trading behaviour here --- from $1.68 to $2.65 then within only a single day it crashed back to $1.81 without any bad news at all nor any market correction at all! It is a manipulation's haven...

Value_Investor Free

08/02/16 10:02 AM

Post #689

How could LPTN drop from $2.65 to $1.81 within only a day without any news at all? Very sick manipulations from the silly MMs!

Value_Investor Free

08/01/16 2:15 PM

Post #688

Re: #678: @tob999 - Crazy low $5.1M market cap!! Insane!

LOL, LPTN has $3.71 per share Huge Positive Book Value plus Zero Debt v.s. it is trading at the joke low $1.98 a share price now! Hyper Undervalued currently...

Value_Investor Free

07/29/16 2:27 PM

Post #687

Re: #681: @Stockexpertpro - LPTN Warning Shorting Low Float Bio Tech Stocks

How could the MMs manipulate LPTN down to as low as $1.81 from $2.65?

Value_Investor Free

07/28/16 11:58 AM

Post #686

Re: #678: @tob999 - Crazy low $5.1M market cap!! Insane!

LPTN is Hyper Undervalued now --- Debt-Free plus $3.71 Book Value and $2.97 Cash Value v.s. at the joke low low $2.0 ~ $2.11 today!

Value_Investor Free

07/25/16 1:49 PM

Post #685

Re: #684: @Value_Investor - LPTN had 25,700 shares shorted in the prior month.

LPTN had 39,600 shares shorted in the current month.

Value_Investor Free

07/25/16 1:48 PM

Post #684

Re: #683: @Value_Investor - Not many shares were shorted as of 06/30/2016!

LPTN had 25,700 shares shorted in the prior month.

Value_Investor Free

07/24/16 5:06 PM

Post #683

Re: #681: @Stockexpertpro - LPTN Warning Shorting Low Float Bio Tech Stocks

Not many shares were shorted as of 06/30/2016! But the number of shorting shares were increased by 54.42% from June 15 to June 30! They will be forced to chase to cover if LPTN breaks up $2.65 in the coming week...

http://shortsqueeze.com/?symbol=lptn

Value_Investor Free

07/22/16 3:24 PM

Post #682

Re: #681: @Stockexpertpro - LPTN Warning Shorting Low Float Bio Tech Stocks

LOL, the sick MM manipulated the price down to as low as $2.02 after LPTN hit the new high $2.65 today! This is the most sick manipulation I've ever seen for a Hyper Undervalued and Hyper Oversold hidden gem!

Stockexpertpro Free

07/22/16 1:09 PM

Post #681

LPTN Warning Shorting Low Float Bio Tech Stocks can be VERY DANGEROUS Just go ask the kid that got caught short KBIO and Loss Over 100,000$

http://www.businessinsider.com/joe-campbell-gofundme-page-for-e-trade-2015-11

Value_Investor Free

07/22/16 12:04 PM

Post #680

Re: #677: @Shaka_Zulu - A close above 2.20 will be nice. Bullish

LPTN should close above $2.3 today since the high is $2.65!

Value_Investor Free

07/22/16 11:54 AM

Post #679

Re: #674: @tob999 - I can smarten up the Ibox if there

Wow, LPTN exploded to $2.65 today! It will test $3 next week!!

tob999

07/22/16 11:13 AM

Post #678

Crazy low $5.1M market cap!! Insane!

https://uk.finance.yahoo.com/q?s=LPTN

Shaka_Zulu Free

07/22/16 11:04 AM

Post #677

A close above 2.20 will be nice. Bullish to 2.96 then 4?

tob999

07/22/16 10:23 AM

Post #676

+21% on substantially increased volume! News comin?

tob999

07/22/16 10:23 AM

Post #675

Ibox updated and redesigned.

tob999

07/22/16 9:17 AM

Post #674

Re: #672: @Value_Investor - LPTN has Zero Debt which is a Sought-After

I can smarten up the Ibox if there are no objections. Any links to latest share structure and other pertinent info would be welcome.

zino

07/21/16 11:28 PM

Post #673

Re: #671: @tob999 - Good timing agreed! Bring on the boom..with this

Float 2.O3 million !!!!!

Value_Investor Free

07/21/16 7:14 PM

Post #672

Re: #671: @tob999 - Good timing agreed! Bring on the boom..with this

LPTN has Zero Debt which is a Sought-After Investment-Grade Nasdaq Bio-Tech stock while the majority of peers have heavy-loaded debts and the endless Huge Dilutions due to the debts conversions...

Hyper Undervalued now since LPTN has $3.71 per share Huge Book Value and $2.97 per share Huge Cash Value v.s. it is trading at the ridiculous low price $1.9099 now!

Hyper Oversold since LPTN just hit the most recent high $4.09! Easy double from here to hit $3.8x ~ $4.xx again...

LPTN has measly 1.9M shares Hyper Tiny float count which is an Hyper Rare find in the Nasdaq world! Easy double within a day as it did on June 20, 2016 --- see the chart below!

LPTN has mere 2.36M shares Hyper Tiny OS which is a Super rare find!

http://finance.yahoo.com/news/lpath-awarded-department-defense-grant-120200294.html

tob999

07/21/16 5:48 PM

Post #671

Re: #670: @Value_Investor - Nice entry at good timing! The Book Value

Good timing agreed! Bring on the boom..with this low sub 2M float it'll be a kaboom. These MM worms and other shorts won't know whats hit em!

Value_Investor Free

07/21/16 12:51 PM

Post #670

Re: #668: @zino - bought in this morning...glta

Nice entry at good timing! The Book Value of LPTN is almost double of the current ridiculous low price! The Cash Value is $2.97 a share!

Value_Investor Free

07/21/16 12:47 PM

Post #669

Re: #667: @zino - can fly here O/S 2,OOO,OOO

Yes. LPTN is Hyper Undervalued now --- $3.71 Huge BV v.s. at $1.91 ~ $2.02 today!

zino

07/21/16 12:42 PM

Post #668

Re: #666: @Value_Investor - We all saw that kinds of manipulation efforts

bought in this morning...glta

zino

07/21/16 12:42 PM

Post #667

Re: #666: @Value_Investor - We all saw that kinds of manipulation efforts

can fly here O/S 2,OOO,OOO

Value_Investor Free

07/20/16 12:39 PM

Post #666

Re: #663: @tob999 - Being held down on low volume. Every time

We all saw that kinds of manipulation efforts almost everyday since LPTN declined from the most recent high $4.09 to $1.82 on July 7...

tob999

07/20/16 12:34 PM

Post #665

Re: #664: @Value_Investor - LPTN hit the New high $2.04 so far!

Undervalued indeed.

Value_Investor Free

07/20/16 12:31 PM

Post #664

Re: #657: @tob999 - Grabbed a few more here today/yesterday. Waiting for

LPTN hit the New high $2.04 so far! It has finally Bottomed out at the New low $1.68! $3.71 per share Huge Book Value! $2.97 per share Huge Cash Value!

http://finance.yahoo.com/news/lpath-awarded-department-defense-grant-120200294.html

tob999

07/20/16 12:31 PM

Post #663

Re: #658: @Value_Investor - Nice bounce yesterday! LPTN hit $1.96 again! We

Being held down on low volume. Every time pps goes past $2 air shares bring it down.

Value_Investor Free

07/19/16 2:53 PM

Post #662

LOL, LPTN has $3.71 Per Share Huge Book Value v.s. trading at the joke low $1.776 ~ $1.89 today! Hyper Undervalued currently! One of the Cheapest Bio-tech hidden gems!

Value_Investor Free

07/18/16 7:12 PM

Post #661

LPTN is up 11.48% in the AH session after some AH news! 20% bouncing so far --- from $1.70 to $2.04...

Value_Investor Free

07/18/16 1:57 PM

Post #660

Who have kept manipulating LPTN down while it just bounced 15.3% from the Fake bottom $1.70 to $1.96 last week?

Older

Lpath Inc fka LPTN

Followers	25	Posters	127
Posts (Today)	0	Posts (Total)	712
Created	11/19/06	Type	Free
Moderators

Lpath Incorporated

4025 Sorrento Valley Blvd.

San Diego, CA 92121

Tel: 858-678-0800

FAX: 858-678-0900

http://www.lpath.com/

Lpath, Inc. is a biotechnology company focused on the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines.

Lpath's ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders.

Lpath, Inc. focuses on the discovery and development of monoclonal antibodies that target bioactive lipids. Numerous lipids that contribute to disease have now been identified through the various efforts of academics and industry. However, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2™ platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.

Lpath has leveraged ImmuneY2 and generated monoclonal antibody drug candidates against several bioactive lipids, including sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), leukotrienes (LTs) and others.

Lpath is currently advancing Lpathomab^TM, a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized to be involved in disorders of the central nervous system (including pain, traumatic brain injury, neurodegeneration), fibrosis, ocular disease and cancer. Lpathomab has demonstrated strong preclinical activity in several animal models of these diseases, including neuropathic pain, diabetic neuropathy, traumatic brain injury and spinal cord injury. Lpathomab is currently in a phase 1 clinical trial.

The company is applying ImmuneY2 to other bioactive lipid targets, many of which are involved in important disease processes (e.g. inflammation, cancer, pain, asthma, and others) thereby adding to our pipeline of novel antibody-based drug candidates.

Lpath has a broad and deep intellectual property position in the bioactive lipid area, with over 50 issued or pending patents in the U.S., with corresponding international applications. Most of these patents were developed in-house using our proprietary technologies and expertise.

Executive Team

Gary Atkinson - Chief Executive Officer, Chief Financial Officer

Background: Mr. Atkinson has more than 20 years of financial management experience. Prior to joining Lpath, he served as the Chief Financial Officer for three private life science companies. In addition, Mr. Atkinson was the Vice President of Finance at Isis Pharmaceuticals, a publicly held pharmaceutical research and development company. He began his career with Ernst & Young, where he earned his CPA designation. Mr. Atkinson is a graduate of Brigham Young University.

Dario A. Paggiarino, M.D. - Sr. Vice President & Chief Development Officer

Background: Dr. Paggiarino brings to Lpath more than 25 years of experience in the pharmaceutical industry, having directed global development programs in a number of therapeutic areas including ophthalmology, pain, inflammatory conditions, and oncology. Most recently, Dr. Paggiarino served as Vice President and Therapeutic Unit Head for retina diseases at Alcon, a division of Novartis. He also served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases, and medical responsibilities for Macugen(R). Earlier in his career, he held R&D positions of increasing responsibility at Angelini Pharmaceuticals, a privately owned company, ultimately serving as president. Later he joined Pharmacia Global R&D where he was clinical program director of ophthalmology with responsibilities for Xalatan(R), the leading glaucoma therapy in the world, and ocular devices such as viscoelastics (Healon(R)) and intraocular lenses (CeeOn(R), Tecnis(R)). Dr. Paggiarino earned his degree in Medicine and General Surgery at the University of Rome La Sapienza and has authored numerous scientific articles.

Gary Woodnutt, Ph.D. - Sr. Vice President & Chief Scientific Officer

Background: Dr. Woodnutt brings to Lpath extensive experience in drug discovery and pharmaceutical research. Prior to joining Lpath, Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer/CovX, but his primary role at CovX, from 2006 to 2012, was as Vice President of Biology Research. From 2002 to 2006, Dr. Woodnutt was the Senior Vice President of Pharmaceutical Research and Development for Diversa Corporation. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he was employed for more than 20 years and rose to the position of Vice President and Head of Biology in the Antimicrobial and Host Defense Group. Dr. Woodnutt received his Ph.D. in biochemistry/physiology from the University of Reading, and he has authored numerous scientific articles.

Roger Sabbadini, Ph.D. - Vice President, Scientific Founder

Background: Dr. Sabbadini was a Professor of Biology for 32 years at San Diego State University and is currently a Professor Emeritus of Biology. He founded three biotechnology companies, including Lpath, that were incubated out of SDSU. Dr. Sabbadini has been interested in the role of bioactive lipids in various diseases, including cancer, ocular disorders, neurotrauma, neuropathic pain, inflammation and heart disease. Dr. Sabbadini’s research focused on developing novel antibody-based therapeutics against bioactive lipids such as S1P and LPA and these antibodies have been advanced into human clinical trials. Dr. Sabbadini earned his Ph.D. at the University of California, Davis.

Leigh Hsu, Ph.D., M.B.A. - Vice President, Corporate Development & Strategy

Background: Dr. Hsu has more than 15 years of business experience in the biotech industry. Prior to Lpath, he held positions of increasing responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics (which became a subsidiary of Schering AG, now Bayer). Dr. Hsu played a key role in Lpath's $517 million licensing deal with Pfizer for iSONEP™, and has extensive deal experience with organizations like Wyeth and GE Healthcare, as well as with several academic and research organizations, including the University of California, the University of Texas, Southwestern Medical Center and the Veterans Medical Research Foundation. He has published numerous scientific papers, primarily in the area of the molecular basis of neurodegenerative diseases. Dr. Hsu received his Ph.D. in Molecular Pathology from the University of California, San Diego, and his M.B.A. from the University of California, Irvine.

Good read: http://seekingalpha.com/article/412101-why-morgan-joseph-expects-triple-digit-gains-for-this-pfizer-partner

ASONEP
http://www.clinicaltrials.gov/ct2/show/NCT00661414

Share Structure

Shares Outstanding	2.36M
Float	1.9M
Authorized Shares	200,000,000
Par Value	0.001

Transfer Agent(s)

Nevada Agency and Transfer Company

Company Officers

Scott Pancoast	President, CEO
Gary Atkinson	Vice President, CFO, Principal Fin. Officer, Principal Acct. Officer
Roger Sabbadini	CSO
Terry Trzcinka	IR

Board Info

Posts Today	0
Posts (Total)	712
Posters	127
Moderators

New Post

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Lpath Inc fka LPTN

Lpath Inc fka LPTN

Join the InvestorsHub Community

Lpath Inc fka LPTN

Lpath's ImmuneY2 platform contains the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders.

Share Structure

Transfer Agent(s)

Company Officers

Board Info